Back to GOLDMAN SACHS GROUP INC GOLDMAN SACHS GROUP INC

CRDLCRDL
Showing 8 of 15 quarters

Position history for GOLDMAN SACHS GROUP INCGOLDMAN SACHS GROUP INC's holdings in CARDIOL THERAPEUTICS INC

Yes. Goldman Sachs holds 333,900 shares of CRDL (Cardiol Therapeutics), worth $353,934, as of its Q2 2026 13F filing. It increased the position by 1,500 shares (+0.5%) from Q1 2026. Goldman Sachs has held CRDL since Q4 2022, across 15 quarterly 13F filings.

Current Value

$353,934

Current Shares

333,900

Total Value Change

+$282,456

Total Shares Change

+297,800

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
333,900
+0.5%
$353,9340.0%$1.06
16
2026-Q1
Increased
332,400
+1.2%
$448,7400.0%$1.35
24
2025-Q4
Increased
328,500
+2.1%
$313,3230.0%$0.95
16
2025-Q3
Increased
321,800
+459.6%
$344,3260.0%$1.07
26
2025-Q2
Increased
57,500
+46.7%
$78,2000.0%$1.36
20
2025-Q1
Increased
39,200
+9.2%
$38,0160.0%$0.97
15
2024-Q4
Decreased
35,900
-0.6%
$45,9520.0%$1.28
0
2024-Q3
Increased
36,100
+53.6%
$71,4780.0%$1.98
20

Other major holders of CRDL: Mirae Asset Global Investments Co., Ltd., CITADEL ADVISORS LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used